CFO sold ~$390K of Gilead Sciences
Scheduled in advanceLoading…
Traded Jun 15, 2026 · Filed Jun 16, 2026
Gilead Sciences's Chief Comm & Corp Aff Officer sold $133K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$132,676
Shares × reported transaction price
39 days after results of May 7, 2026, 50 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $124.30 on Jun 15, 2026, 17% above its 52-week low and 20% below its high, after a 6% drop over the previous 30 trading days
52-week range $105.93 (Jun 25, 2025) to $155.80 (Feb 11, 2026), 37% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.65 on May 1, 2026. Describes the past only, not a forecast
A WARN layoff notice covering 108 workers was filed in California on April 30, 2026.
From the official state WARN list, 46 days before the trade. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Trodelvy on Jun 24, 2026, 9 days after this trade.
New use approved (efficacy supplement). Active ingredient: Sacituzumab Govitecan-Hziy. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.2% | -1.0% | +0.8% |
| 30 days | +7.0% | +0.3% | +6.7% |
| 90 days | +16.6% | +2.2% | +14.4% |
Past results only. Not a forecast.
CFO sold ~$390K of Gilead Sciences
Scheduled in advanceOfficer sold ~$390K of Gilead Sciences
Scheduled in advanceCEO sold ~$1.5M of Gilead Sciences
Scheduled in advance
